VVector Bio Revenue
Biotechnology Research • 
6750 Rue Hutchison, 201, Canada • 1-10 Employees
VVector Bio revenue & valuation
| Annual revenue | $427,775 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,400,000 |
| Total funding | $250,000 |
Key Contact at VVector Bio
Omar Farnos Villar
Director of Research Development
Company overview
| Headquarters | 6750 Rue Hutchison, 201, Montreal, Quebec H3N 1Y4, CA |
| Phone number | +120192020 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Analytics, Manufacturing, Process Development, Vaccines, AAV, Viral Vectors, Cell Therapy, Downstream Processing, Gene Therapy, Bioreactors, Bioprocessing, Recombinant Protein, Cell Line Development, Biomanufacturing, Adeno-Associated Virus, Lentivirus, Upstream Processing, Enveloped Vlps, Plasmid Engineering |
| Founded | 2019 |
| Employees | 1-10 |
| Socials |
VVector Bio Email Formats
VVector Bio uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@vvectorbio.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@vvectorbio.com | 66.7% |
{first initial}.{last name} | j.doe@vvectorbio.com | 33.3% |
About VVector Bio
VVector Bio is helping biotech companies efficiently manufacture viral vectors for cell and gene therapy and vaccines using proprietary, cutting-edge technologies available for licensing. We have deep expertise in developing scalable processes for viruses used in these therapies and vaccines, including Adeno-associated virus (AAV), lentivirus (LVV), enveloped VLPs, adenovirus, and other virus-like particles such as NDV. Our processes are fully scalable and ready for transfer to a GMP facility. In the context of AAV, we are developing two proprietary manufacturing technologies aimed at improving and simplifying the manufacturing process. Our first technology is a single plasmid system, which optimizes the traditional three-plasmid transfection method, reducing overall costs by 20% and increasing AAV manufacturing yields by 5x. The second technology is a high-producer cell line capable of producing AAV at orders of magnitude higher yields than current industry standards.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
VVector Bio Tech Stack
Discover the technologies and tools that power VVector Bio's digital infrastructure, from frameworks to analytics platforms.
Form builders
Analytics
JavaScript libraries
Maps
Page builders
JavaScript libraries
Web servers
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
United States
Australia
Sweden
Israel
Korea, Republic of
United Kingdom
Frequently asked questions
4.8
40,000 users
